Tamiflu bolsters Chugai's first quarter but some underlying weakness
This article was originally published in Scrip
A big increase in seasonal sales of the flu antiviral Tamiflu (oseltamivir) boosted the top line at Roche's Japanese affiliate Chugai in the first quarter ended 31 March, although there was some weakness in underlying performance due to a slow start for the long-acting erythropoiesis stimulating agent Mircera (peg-epoetin beta).
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.